search
drug discovery
Trends
- 1Basecamp Research raises $140M to map biodiversity with AI▼UK-based Basecamp Research raised $140M to map global biodiversity for drug discovery. By training AI on genetic data fr
UK-based Basecamp Research has raised $140 million to map global biodiversity for drug discovery. The company trains AI on genetic data from unexplored organisms to help design new therapies. Commenters note that scaling the work will depend on proving safety in human trials and ensuring fair benefit-sharing with the countries and communities where genetic material originates.
- 2Roche outlines plans for autonomous AI laboratories▼Roche outlines plans to move towards autonomous AI labs
Roche has outlined plans to move towards autonomous AI laboratories, according to a Reuters report. The Swiss pharmaceutical company intends to use artificial intelligence to run elements of its research operations with reduced human involvement, a step that would put it among the first major drugmakers to pursue fully automated, AI-driven labs.
- 3Scientists Identify New Potential Target for Hypertension Treatment▼Scientists Discover a New Potential Treatment Target for High Blood Pressure
Researchers have identified a new potential treatment target for high blood pressure, a condition affecting over a billion people worldwide and a leading risk factor for heart disease and stroke. The discovery could open the door to new drug development beyond existing blood pressure medications. Details of the findings and their clinical significance remain limited.
- 4AI's biggest payoff could be better medicines●The AI boom’s biggest payoff could be better medicines
Commentators argue that the clearest real-world benefit of the current AI boom may come in medicine, where artificial intelligence can speed up drug discovery, identify promising compounds, and shorten the path from lab research to approved treatments. The claim suggests that beyond consumer chatbots and productivity tools, healthcare and pharmaceuticals could be where AI delivers its most valuable results for society.
- 5Insilico Medicine signs multimillion AI drug discovery deal▼Insilico Medicine strikes tens-of-millions AI co-development deal with unnamed foundation-model lab
Insilico Medicine has signed a co-development deal worth tens of millions of dollars with an unnamed foundation-model laboratory, joining forces to apply large AI models to drug discovery. The Hong Kong-based biotech, known for using generative AI to design drug candidates, has not disclosed its partner or the exact terms, leaving observers speculating about which AI lab is behind the agreement.
- 6
Anthropic has established its own wet laboratory as it expands its AI-driven drug discovery programme, according to Reuters. The lab will let the company test biological hypotheses generated by its AI models in real experiments. Observers see it as a notable step for an AI firm moving from software into hands-on biology and pharmaceutical research.
- 7AI helping scientists advance biological design in health research▼How AI is allowing scientists to advance biological design for health research: HealthLink
Scientists are increasingly using artificial intelligence to speed up biological design for health research, applying AI tools to engineer proteins, model biological systems and accelerate drug and therapy development. The approach is being highlighted as a way to cut research timelines and expand what laboratories can design, with health reporters examining how the technology is changing biomedical science and what it could mean for future treatments.
- 8Snorkel AI raises $350 million, Enveda secures $311 million●Snorkel AI підняв 350 мільйонів доларів. Enveda підняв 311 мільйонів. Жоден із них не продає чат-бота. 23 вересня 2026 S
Snorkel AI closed a $350 million Series E round led by Insight Partners on September 23, 2026, while biotech startup Enveda raised $311 million in its own Series E the same day. Neither company sells a chatbot, highlighting investor appetite for AI firms focused on data infrastructure and drug discovery rather than consumer chat products.